Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers
Together, these results provide a roadmap for improving alcohol use disorder treatment outcomes via precision application of existing compounds.
Authors
- Zahra Z. Farahbakhsh (ORCID: https://orcid.org/0000-0002-0909-7377)
- Suzanne O. Nolan (ORCID: https://orcid.org/0000-0002-2094-8793)
- Snigdha Mukerjee (ORCID: https://orcid.org/0000-0002-5359-3087)
- Alex Brown (ORCID: https://orcid.org/0000-0001-8585-5953)
- Cody A. Siciliano (ORCID: https://orcid.org/0000-0001-9871-2089)
Institutions
- Vanderbilt University (US)
- Vanderbilt Health (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1038/s43856-025-01369-6
- Primary Topic
- Neurotransmitter Receptor Influence on Behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health